|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic and Translational Investigations |
1 Divisions of Hematology and Hematopoietic Cell Transplantation and Neurosciences and Beckman Research Institute, City of Hope National Medical Center, Duarte, CA
2 Neurosurgical Oncology Laboratory, Department of Neurosurgery, Brigham and Women's Hospital and Children's Hospital, Harvard Medical School, Department of Neurosurgery, University Hospital Hamburg-Eppendorf
3 Neurosurgical Oncology Laboratory, Department of Neurosurgery, Brigham and Women's Hospital and Children's Hospital, Harvard Medical School
4 Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, and Departments of Surgery and Neurosurgery, Tufts-New England Medical Center and Tufts University School of Medicine
 |
Abstract |
|---|
Brain metastases are an increasingly frequent and serious clinical problem for cancer patients, especially those with advanced melanoma. Given the extensive tropism of neural stem/progenitor cells (NSPCs) for pathological areas in the central nervous system, we expanded investigations to determine whether NSPCs could also target multiple sites of brain metastases in a syngeneic experimental melanoma model. Using cytosine deaminase-expressing NSPCs (CD-NSPCs) and systemic 5-fluorocytosine (5-FC) pro-drug administration, we explored their potential as a cell-based targeted drug delivery system to disseminated brain metastases. Our results indicate a strong tropism of NSPCs for intracerebral melanoma metastases. Furthermore, in our therapeutic paradigm, animals with established melanoma brain metastasis received intracranial implantation of CD-NSPCs followed by systemic 5-FC treatment, resulting in a significant (71%) reduction in tumor burden. These data provide proof of principle for the use of NSPCs for targeted delivery of therapeutic gene products to melanoma brain metastases.
Key Words: brain metastases, cytosine deaminase, gene therapy, melanoma, neural progenitor cells, neural stem cells, tumor targeting
This article has been cited by other articles:
|
|
 |
|
  T. L. Sims Jr., J. B. Hamner, R. A. Bush, R. F. Williams, J. Zhou, S. U. Kim, K. S. Aboody, M. K. Danks, and A. M. Davidoff Neural Progenitor Cell-mediated Delivery of Interferon Beta Improves Neuroblastoma Response to Cyclophosphamide Ann. Surg. Oncol., November 1, 2008; 15(11): 3259 - 3267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kendall, J. Najbauer, H. F. Johnston, M. Z. Metz, S. Li, M. Bowers, E. Garcia, S. U. Kim, M. E. Barish, K. S. Aboody, et al. Neural Stem Cell Targeting of Glioma Is Dependent on Phosphoinositide 3-Kinase Signaling Stem Cells, June 1, 2008; 26(6): 1575 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kucerova, V. Altanerova, M. Matuskova, S. Tyciakova, and C. Altaner Adipose Tissue-Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy Cancer Res., July 1, 2007; 67(13): 6304 - 6313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Palmieri, A. F. Chambers, B. Felding-Habermann, S. Huang, and P. S. Steeg The Biology of Metastasis to a Sanctuary Site Clin. Cancer Res., March 15, 2007; 13(6): 1656 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Danks, K. J. Yoon, R. A. Bush, J. S. Remack, M. Wierdl, L. Tsurkan, S. U. Kim, E. Garcia, M. Z. Metz, J. Najbauer, et al. Tumor-Targeted Enzyme/Prodrug Therapy Mediates Long-term Disease-Free Survival of Mice Bearing Disseminated Neuroblastoma Cancer Res., January 1, 2007; 67(1): 22 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-K. Kim, S. U. Kim, I. H. Park, J. H. Bang, K. S. Aboody, K.-C. Wang, B.-K. Cho, M. Kim, L. G. Menon, P. M. Black, et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin. Cancer Res., September 15, 2006; 12(18): 5550 - 5556. [Abstract] [Full Text] [PDF]
|
|
|
|
